Non-insured Health Benefits Program Now Covers Dexcom G6 Continuous Glucose Monitoring System for Children and Adolescents on Intensive Insulin Therapy
September 13 2021 - 1:00PM
Business Wire
- Dexcom G6 is the first Continuous Glucose Monitoring (CGM)
System to be listed by the NIHB Drug Benefit program.
Dexcom, Inc. (NASDAQ: DXCM), a leader in real-time continuous
glucose monitoring (CGM), is pleased to announce the Dexcom G6 CGM
System is now covered by the Non-Insured Health Benefits (NIHB)
Program for people living with diabetes who are between 2 and 19
years old and require intensive insulin therapy. This expanded
coverage will give more First Nations and Inuit children and
adolescents access to this standard of care, potentially helping
them to have more control over a life-long chronic illness.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210913005728/en/
NIHB clients ages 2 to 19 on intensive
insulin therapy are now eligible for coverage of the Dexcom G6 CGM
System. (Photo: Business Wire)
“Indigenous, First Nations and Inuit communities are
disproportionately impacted by diabetes, yet I’ve seen how greater
access to CGM for this population can mean better glucose control,
which leads to improved health outcomes and reduced risk of
developing diabetes-related complications,” said Dr. Jeff
Winterstein, an Edmonton-based internal medicine specialist who
works with many NIHB patients who live with diabetes. “Furthermore,
CGM can help to bridge the distance between remote communities and
care providers. The Dexcom CLARITY software and app allows me to
remotely see a patient’s glucose data and trends over time so I can
make the appropriate adjustments and treatment decisions.”
Dexcom CGM use is proven to improve glycemic control1,2 and can
reduce the risk of costly long-term diabetes-related complications
compared to fingerstick monitoring.3 As part of the NIHB coverage
program, clients ages 2 - 19 can obtain their Dexcom G6 CGM
supplies directly from their local pharmacy.
“Expanded access to CGM for clients enrolled in NIHB is an
important step forward in creating a more equitable healthcare
system across the country,” says Laura Endres, Vice President and
General Manager of Dexcom Canada. “Not only does CGM positively
impact the health of the client, but it can also support families
managing diabetes as well as parents can have more peace of mind
monitoring their child’s levels from a distance.”
The Dexcom G6 CGM System includes a small, wearable sensor that
measures glucose just below the skin; a transmitter to continuously
and wirelessly send glucose levels to a display device; and a
compatible smart device* or receiver that displays real-time
glucose data to users without the need for fingersticks† or
scanning.
With real-time alerts, including a predictive Urgent Low Soon
alert, the Dexcom G6 can warn the user in advance of hypoglycemia —
allowing time to take appropriate action before it happens — day or
night. When using the Dexcom Follow App‡, parents can also access
their child's glucose levels remotely and be alerted if they are
going out of target glucose range.
For more information about the coverage criteria for Non-Insured
Health Benefits clients, please visit
www.dexcom.com/en-CA/public-coverage.
To search the online NIHB Drug Benefit List for Dexcom G6
coverage details, go to
https://nihb.express-scripts.ca/NIHBProvider/benefits/pharmacy?page=drugbenefit-grid&benefit=pharmacy
About Dexcom, Inc.
Dexcom, Inc. empowers people to take control of diabetes through
innovative continuous glucose monitoring (CGM) systems.
Headquartered in San Diego, California in the United States, and
with operations in Canada, Dexcom has emerged as a leader of
diabetes care technology. By listening to the needs of users,
caregivers, and providers, Dexcom simplifies and improves diabetes
management around the world. For more information about Dexcom CGM,
visit www.dexcom.com.
† If your glucose alerts and readings from the G6 do not match
symptoms or expectations, use a blood glucose meter to make
diabetes treatment decisions. * For a list of compatible devices,
please visit dexcom.com/compatibility ‡ Following requires the
Dexcom Follow App and an Internet connection. Followers should
always confirm readings on the Dexcom G6 App or Receiver before
making treatment decisions.
References _____________________________
1Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous
glucose monitoring on glycemic control in adults with type 1
diabetes using insulin injections: The DIAMOND randomized clinical
trial. JAMA 2017;317(4):371-8. 2Welsh JB, Gao P, Derdzinski M, et
al. Accuracy, Utilization, and Effectiveness Comparisons of
Different Continuous Glucose Monitoring Systems. Diabetes Technol
Ther 2019;21(3):128-32. 3 Roze S, Isitt J, Smith-Palmer J, Lynch P.
Evaluation of the Long-Term Cost-Effectiveness of the Dexcom G6
Continuous Glucose Monitor Versus Self Monitoring of Blood Glucose
in People with Type 1 Diabetes in Canada. Poster presentation
presented at: 2020 Canadian Association for Population
Therapeutics; October 27, 2020.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210913005728/en/
Alena Atkinson, 705.206.9991 Veritas Communications
atkinson@veritasinc.com
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Jun 2024 to Jul 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Jul 2023 to Jul 2024